In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it can be hard to find detailed data on the market, and expert insights on potential change to the regulatory environment. 

Our Orphan Drug Report 2022 addresses these challenges, drawing on the breadth and depth of data available across the Evaluate portfolio to answer some of the big questions about this increasingly competitive – and lucrative space. 

Download our infographic for highlights from the full report (coming soon). 



Orphan drug sales growth
Orphan drugs face growing competition
Big pharma is increasingly reliant on orphans
Regulators are tightening the screws
Orphans out-size mass market drugs